席夫碱 - 泊洛沙姆P85组合对肾癌的抗癌活性。
Anticancer activity of Schiff base-Poloxamer P85 combination against kidney cancer.
作者信息
Doğan Ayşegül, Demirci Selami, Telci Dilek, Canikyan Serli, Kongur Merve, Dede Bülent, Şahin Fikrettin
机构信息
Genetics and Bioengineering Department, Faculty of Engineering, Yeditepe University, Kayisdagi, Istanbul, Turkey.
National Cancer Instıtute, CDBL, NIH, Frederick, MD, USA.
出版信息
Int Urol Nephrol. 2018 Feb;50(2):247-255. doi: 10.1007/s11255-017-1782-9. Epub 2017 Dec 29.
PURPOSE
Renal cell carcinoma (RCC) accounts for approximately 80% of the primary renal cancers, and current treatment strategies are not sufficient to provide a certain solution. Since there are not many treatment options, interest in discovery of alternative drugs has increased.
METHODS
In the current study, anticancer activity of a novel heterodinuclear Cu(II)-Mn(II) complex (Schiff base-SB) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (pluronic) P85 was tested against RCC. Cell viability, apoptosis and gene expression analysis were conducted in vitro by using Renca cells.
RESULTS
The results revealed that the SB-P85 combination decreased cell proliferation by increasing the apoptotic gene expressions and apoptosis. Renca-injected BALB/c mice were used to mimic early stage of RCC model. Treatment with SB-P85 combination suppressed tumor formation and growth compared to baseline.
CONCLUSION
Overall, SB-P85 showed promising anticancer activity against RCC in vitro and in vivo.
目的
肾细胞癌（RCC）约占原发性肾癌的80%，目前的治疗策略不足以提供确切的解决方案。由于治疗选择不多，人们对发现替代药物的兴趣增加。
方法
在本研究中，测试了一种新型异双核铜（II）-锰（II）配合物（席夫碱-SB）与聚环氧乙烷和聚环氧丙烷嵌段共聚物（普朗尼克）P85联合对肾细胞癌的抗癌活性。使用Renca细胞在体外进行细胞活力、凋亡和基因表达分析。
结果
结果显示，SB-P85组合通过增加凋亡基因表达和凋亡来降低细胞增殖。注射Renca细胞的BALB/c小鼠用于模拟肾细胞癌模型的早期阶段。与基线相比，SB-P85组合治疗抑制了肿瘤形成和生长。
结论
总体而言，SB-P85在体外和体内对肾细胞癌均显示出有前景的抗癌活性。
Zotero 插件